Logo image of OMGA

OMEGA THERAPEUTICS INC (OMGA) Stock Fundamental Analysis

NASDAQ:OMGA - Nasdaq - US68217N1054 - Common Stock - Currency: USD

0.2298  +0.01 (+4.22%)

After market: 0.1962 -0.03 (-14.62%)

Fundamental Rating

2

Overall OMGA gets a fundamental rating of 2 out of 10. We evaluated OMGA against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of OMGA have multiple concerns. OMGA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OMGA had negative earnings in the past year.
In the past year OMGA has reported a negative cash flow from operations.
In the past 5 years OMGA always reported negative net income.
OMGA had a negative operating cash flow in each of the past 5 years.
OMGA Yearly Net Income VS EBIT VS OCF VS FCFOMGA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -47.86%, OMGA is in line with its industry, outperforming 48.50% of the companies in the same industry.
Looking at the Return On Equity, with a value of -633.21%, OMGA is doing worse than 81.77% of the companies in the same industry.
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROIC N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OMGA Yearly ROA, ROE, ROICOMGA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 100 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMGA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMGA Yearly Profit, Operating, Gross MarginsOMGA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -1K -2K -3K -4K

More info and screens

1

2. Health

2.1 Basic Checks

OMGA does not have a ROIC to compare to the WACC, probably because it is not profitable.
OMGA has more shares outstanding than it did 1 year ago.
The debt/assets ratio for OMGA has been reduced compared to a year ago.
OMGA Yearly Shares OutstandingOMGA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M 50M
OMGA Yearly Total Debt VS Total AssetsOMGA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

OMGA has an Altman-Z score of -4.93. This is a bad value and indicates that OMGA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -4.93, OMGA is doing worse than 61.77% of the companies in the same industry.
A Debt/Equity ratio of 1.00 is on the high side and indicates that OMGA has dependencies on debt financing.
OMGA's Debt to Equity ratio of 1.00 is on the low side compared to the rest of the industry. OMGA is outperformed by 79.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Altman-Z -4.93
ROIC/WACCN/A
WACC10.3%
OMGA Yearly LT Debt VS Equity VS FCFOMGA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

OMGA has a Current Ratio of 1.61. This is a normal value and indicates that OMGA is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of OMGA (1.61) is worse than 81.59% of its industry peers.
OMGA has a Quick Ratio of 1.61. This is a normal value and indicates that OMGA is financially healthy and should not expect problems in meeting its short term obligations.
OMGA has a Quick ratio of 1.61. This is amonst the worse of the industry: OMGA underperforms 80.53% of its industry peers.
Industry RankSector Rank
Current Ratio 1.61
Quick Ratio 1.61
OMGA Yearly Current Assets VS Current LiabilitesOMGA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

OMGA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.06%, which is quite impressive.
The Revenue has grown by 184.04% in the past year. This is a very strong growth!
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%

3.2 Future

The Earnings Per Share is expected to grow by 23.60% on average over the next years. This is a very strong growth
OMGA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 150.92% yearly.
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%

3.3 Evolution

OMGA Yearly Revenue VS EstimatesOMGA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
OMGA Yearly EPS VS EstimatesOMGA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

OMGA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year OMGA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMGA Price Earnings VS Forward Price EarningsOMGA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMGA Per share dataOMGA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

OMGA's earnings are expected to grow with 20.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.8%
EPS Next 3Y20.55%

More info and screens

0

5. Dividend

5.1 Amount

OMGA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OMEGA THERAPEUTICS INC

NASDAQ:OMGA (2/14/2025, 8:00:02 PM)

After market: 0.1962 -0.03 (-14.62%)

0.2298

+0.01 (+4.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)03-06 2025-03-06/amc
Inst Owners87.7%
Inst Owner Change-69.18%
Ins Owners1.62%
Ins Owner Change0%
Market Cap12.72M
Analysts81.82
Price Target9.44 (4007.92%)
Short Float %9.71%
Short Ratio10.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.6%
Min EPS beat(2)-6.31%
Max EPS beat(2)19.51%
EPS beat(4)2
Avg EPS beat(4)6.61%
Min EPS beat(4)-6.31%
Max EPS beat(4)19.51%
EPS beat(8)5
Avg EPS beat(8)8.26%
EPS beat(12)8
Avg EPS beat(12)10.33%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)113.47%
Min Revenue beat(2)106.48%
Max Revenue beat(2)120.46%
Revenue beat(4)4
Avg Revenue beat(4)84.74%
Min Revenue beat(4)41.91%
Max Revenue beat(4)120.46%
Revenue beat(8)8
Avg Revenue beat(8)95.37%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-16.99%
EPS NQ rev (1m)15.75%
EPS NQ rev (3m)25.18%
EPS NY rev (1m)1.83%
EPS NY rev (3m)-4.95%
Revenue NQ rev (1m)-4.71%
Revenue NQ rev (3m)101.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)23.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B 1.1
P/tB 1.1
EV/EBITDA N/A
EPS(TTM)-1.33
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0.15
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.86%
ROE -633.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.09%
ROA(5y)-109.27%
ROE(3y)-99.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.3%
Cap/Sales 25.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.61
Quick Ratio 1.61
Altman-Z -4.93
F-Score4
WACC10.3%
ROIC/WACCN/A
Cap/Depr(3y)125.73%
Cap/Depr(5y)129.45%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y34.35%
EPS Next 2Y24.8%
EPS Next 3Y20.55%
EPS Next 5Y23.6%
Revenue 1Y (TTM)184.04%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%214.32%
Revenue Next Year233.18%
Revenue Next 2Y29.68%
Revenue Next 3Y37.19%
Revenue Next 5Y150.92%
EBIT growth 1Y32.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.82%
EBIT Next 3Y6.19%
EBIT Next 5YN/A
FCF growth 1Y37.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y38.41%
OCF growth 3YN/A
OCF growth 5YN/A